Kenox Pharmaceuticals and Lactiga US have announced a strategic partnership to progress the development of new mucosal-targeted secretory IgA (sIgA) therapies, focusing on enhancing immunity for immunodeficient individuals.
The partnership is backed by a substantial small business technology transfer grant to Lactiga from the National Institute of Allergy and Infectious Diseases.
Go deeper with GlobalData
It will utilise Kenox’s expertise in nasal and inhaled pharma development and manufacturing to expedite the therapies’ preclinical development.
The grant will further Lactiga’s sIgA technology platform and broaden Kenox’s inhaled and intranasal biologic delivery system offerings.
Kenox Pharmaceuticals CEO and president Sitaram Velaga stated: “This collaboration, combined with the prestigious grant, underscores the immense potential of this innovative approach to address the unmet needs of immunodeficient patients.”
The company, established in 2018 and based in the US state of New Jersey, focuses on pharma aerosol product development, which includes a range of inhalers and sprays.
These encompass soft mist inhalers, dry powder inhalers, pressurised metred-dose inhalers, nebulisers, nasal sprays and ophthalmic products for small and biologic molecules.
It provides services in formulation design, fill-finish, testing and compounding in accordance with compendial monographs.
The partnership represents a step forward in nasal immunotherapies development, with the potential to substantially impact the quality of life for immunodeficient people.
Lactiga co-founder and CEO Rikin Mehta stated: “Immunologists have long sought a nasal sIgA spray to reduce recurrent respiratory infections, especially in compromised individuals – a major unmet medical need costing the healthcare system billions of dollars.”
Lactiga focuses on sIgA-based therapeutics and aims to improve the lives of vulnerable and compromised populations by developing targeted treatments for infectious and inflammatory conditions.
